Ampersand Exits TJO@Pack to Alcami in Strategic CDMO Consolidation

Ampersand Capital Partners has sold TJO@Pack, a Netherlands-based contract development and manufacturing organization (CDMO) specializing in pharmaceutical packaging, to Alcami, the Wilmington, North Carolina-based contract manufacturer. Financial terms weren't disclosed, but the transaction marks Ampersand's exit from an investment it's held since backing TJO@Pack's management team in improving operations and expanding service capabilities.

The deal extends Alcami's European footprint and adds specialized packaging expertise to a platform that already provides drug development, testing, and manufacturing services across sterile and non-sterile formats. For Ampersand, it's a textbook mid-market healthcare exit — buy a niche operator, professionalize it, sell it to a larger platform that can deploy more capital.

TJO@Pack operates out of Barneveld, Netherlands, where it handles secondary packaging — the bottles, blister packs, and cartons that house pharmaceutical products after primary manufacturing. The company works with both branded pharma and generic drug makers, providing serialization, labeling, and packaging lines that meet EU regulatory standards. It's the kind of unglamorous, high-compliance work that underpins drug supply chains but rarely makes headlines.

What makes this exit notable isn't the company — it's the consolidation pattern it reflects. The CDMO sector has been rolling up for years, driven by pharma companies' preference to outsource manufacturing complexity rather than build it internally. Specialized service providers like TJO@Pack become acquisition targets for larger platforms seeking to offer clients one-stop manufacturing solutions across geographies and capabilities.

Alcami itself is a product of consolidation. The company was formed through the 2017 merger of AAIPharma Services and Cambridge Major Laboratories, backed by private equity firm GTCR. Since then, it's executed a steady drumbeat of acquisitions to build scale and capability density. The TJO@Pack addition brings European packaging into a portfolio that already spans analytical testing, formulation development, and API manufacturing.

The strategic logic is straightforward: pharmaceutical companies want fewer vendor relationships, not more. If Alcami can take a drug candidate from early development through commercial manufacturing and packaging — and do it across both U.S. and European markets — it's more valuable than a provider that only handles one piece of that chain.

Geography matters here. TJO@Pack's Netherlands location gives Alcami a manufacturing presence inside the EU, which matters for European regulatory compliance and supply chain efficiency. Pharma companies selling in Europe often prefer EU-based secondary packaging to avoid cross-border logistics headaches and meet local labeling requirements. Alcami didn't have that before. Now it does.

The company didn't disclose how TJO@Pack's revenue or client roster will integrate, but secondary packaging operations are typically lower-margin than upstream manufacturing. The value isn't in the packaging lines themselves — it's in being able to tell a client, "We'll handle your drug from API synthesis through final carton," and mean it across two continents.

Ampersand Capital Partners, a Wellesley, Massachusetts-based middle-market firm, has a long track record in healthcare services and outsourced business services. The firm's investment in TJO@Pack fit its operational value creation playbook — back capable management, improve systems and processes, position for strategic sale.

The firm didn't specify when it originally invested in TJO@Pack or how long it held the asset, but the exit timing aligns with a broader wave of CDMO consolidation. According to industry data, the global CDMO market is expected to grow from roughly $120 billion in 2023 to over $200 billion by 2030, driven by continued pharma outsourcing and the rise of complex biologics that require specialized manufacturing.

Private equity firms have been major drivers of that consolidation. Mid-market shops like Ampersand buy niche CDMOs, professionalize operations, then sell to larger PE-backed platforms or strategics that can leverage the capabilities across a broader client base. It's a proven strategy, but it requires picking sub-sectors where fragmentation still exists and where scale actually creates value.

Packaging fits that profile. The market remains fragmented across regions and service types, and there's real efficiency in consolidating packaging with upstream manufacturing. That made TJO@Pack an attractive bolt-on for Alcami — and made Ampersand's exit relatively clean.

The table above shows how CDMO consolidation has escalated from mid-market roll-ups to mega-cap strategic acquisitions. Ampersand's exit sits in the first category — selling a specialized asset into a larger platform still being built. The real question is whether Alcami itself becomes an exit candidate in the next few years, or whether GTCR continues to build scale before testing the strategic buyer market.

Secondary packaging used to be an afterthought — something pharma companies handled in-house or outsourced to the lowest bidder. That changed with serialization mandates, temperature-sensitive biologics, and increasingly complex supply chains. Packaging is now a regulated, data-intensive process that requires traceability, compliance infrastructure, and integration with upstream manufacturing.

This deal is small in dollar terms — likely well under $500 million based on typical secondary packaging valuations — but it's representative of a larger thesis that's driven billions in CDMO M&A over the past five years.

Pharmaceutical companies are outsourcing more manufacturing than ever. Branded drug makers want to focus capital on R&D and commercial operations, not building and maintaining manufacturing plants. Biotech startups lack the capital to build their own facilities. Even mid-sized pharma companies find it cheaper to contract out manufacturing than to maintain underutilized capacity in-house.

That demand is pushing CDMOs to expand service offerings horizontally (adding new capabilities like packaging, testing, formulation) and geographically (establishing facilities in multiple regulatory zones to serve global clients). Companies that can do both become significantly more valuable than single-site, single-service providers.

Private equity firms have capitalized on that dynamic by building multi-site CDMO platforms through M&A. The playbook is consistent: acquire a core asset with strong management and a defensible market position, bolt on complementary capabilities through smaller acquisitions, scale the combined platform, then exit to a strategic or a larger PE firm at a step-up multiple.

Ampersand's exit is the middle chapter of that story. TJO@Pack was the bolt-on. Alcami is the platform being built. The next chapter is Alcami's eventual exit — whether to a pharma company looking to bring manufacturing in-house, a larger CDMO consolidator, or another PE firm with the capital to take it to the next level of scale.

Despite years of M&A, the CDMO market remains fragmented. Hundreds of small and mid-sized providers operate across specific geographies, therapeutic areas, and service types. Europe in particular still has dozens of independent packaging, formulation, and API manufacturers that could become acquisition targets for U.S.-based platforms looking to expand internationally.

The risk is overcapacity. If too many platforms chase the same clients and the same bolt-on targets, pricing power erodes and multiples compress. Some analysts argue the CDMO market is already oversupplied in certain segments, particularly in basic generics manufacturing. The winning platforms will be those that specialize in higher-complexity services — biologics, sterile fill-finish, complex formulations — where regulatory barriers and technical expertise create defensibility.

The press release offered no details on post-acquisition integration plans, but CDMO acquisitions typically follow a consistent pattern. Existing management stays in place to ensure continuity. The acquired site operates under its existing brand and regulatory licenses during a transition period. Over 12-24 months, systems are integrated — quality management, IT infrastructure, procurement — and the site begins cross-selling services to the acquirer's existing clients.

For TJO@Pack's roughly 200 employees (estimated based on facility size and industry norms), the near-term impact is minimal. Manufacturing operations continue. The bigger question is whether Alcami invests in expanding the Barneveld facility's capabilities — adding new packaging lines, upgrading automation, or broadening service offerings — or whether it treats the site primarily as a geographic foothold with modest organic growth expectations.

PE-backed CDMOs tend to prioritize margin improvement over headcount growth, which means efficiency gains and automation investments are more likely than significant hiring. If Alcami follows that pattern, TJO@Pack's workforce might not grow much, but the site's strategic importance within the broader platform likely increases.

Client contracts are the other variable. TJO@Pack's existing pharma clients will want assurance that service quality and regulatory compliance won't slip during the transition. Alcami's reputation and scale should help there, but integration risk is real — especially when combining IT systems, quality processes, and regulatory filings across borders.

While deal terms weren't disclosed, industry valuation benchmarks offer context. Secondary packaging CDMOs typically trade at 8-12x EBITDA in private transactions, depending on client concentration, regulatory compliance track record, and facility utilization rates. If TJO@Pack generated $30-50 million in revenue (a reasonable estimate for a facility of its profile), EBITDA margins in the 12-18% range would imply an enterprise value in the low-to-mid nine figures.

That would represent a solid return for Ampersand if it bought in at a lower multiple and improved margins during its hold period. The mid-market PE playbook often targets 2.5-3.5x cash-on-cash returns over a 4-6 year hold. Without knowing the entry multiple or hold duration, it's impossible to calculate Ampersand's IRR, but the exit to a strategic platform buyer suggests the investment met or exceeded return targets.

The multiple expansion opportunity is clear: standalone packaging businesses trade at the lower end of the range, while integrated platforms command premiums. Alcami's strategy is to aggregate sub-scale assets like TJO@Pack, integrate them into a broader service offering, and eventually exit at a platform multiple rather than a sum-of-parts valuation.

That arbitrage — buying at 9x, improving operations and adding capabilities, selling at 15x — is the engine behind PE-driven CDMO consolidation. It works as long as there are still fragmented, sub-scale targets to acquire and strategic buyers willing to pay platform multiples for integrated service providers.

Cross-border CDMO acquisitions introduce integration complexity that domestic deals don't. Regulatory frameworks differ between the U.S. and EU. Quality management systems may not align. IT infrastructure integration across an ocean is harder than across state lines. And client contracts often include change-of-control provisions that require renegotiation or consent when ownership changes.

TJO@Pack's Netherlands location also exposes Alcami to European labor regulations, which are more restrictive than U.S. norms. Layoffs are harder. Benefits are more generous. Works councils have influence over operational decisions. That limits Alcami's flexibility to restructure the site if margins disappoint or if integration doesn't go as planned.

Currency risk is another factor. If TJO@Pack's revenue is primarily in euros but Alcami's debt and investor reporting are in dollars, exchange rate fluctuations can erode returns. Some PE-backed platforms hedge currency exposure, but it's an additional layer of financial management that standalone U.S. operators don't face.

The bigger strategic risk is client concentration. If TJO@Pack derives a significant portion of revenue from one or two large pharma clients, losing a contract post-acquisition could crater the site's economics. Ampersand's due diligence presumably vetted that risk, but client retention is never guaranteed when ownership and management change.

Ampersand's exit environment is favorable. Healthcare services and life sciences tools remain in high demand. Strategic buyers have capital to deploy. And the CDMO sector's long-term growth drivers — aging populations, rising drug approvals, continued outsourcing — remain intact despite short-term headwinds like GLP-1 manufacturing bottlenecks and generic pricing pressure.

For mid-market PE firms, the lesson is that specialized, defensible healthcare services businesses still command premium exit valuations — if you pick the right sub-sector and execute operationally. Ampersand didn't swing for the fences with TJO@Pack. It didn't try to build a standalone platform or force rapid revenue growth. It backed a competent management team in a niche market, made operational improvements, and sold to a logical strategic buyer. That's textbook mid-market value creation.

The harder question is whether that playbook still works in five years. As CDMO consolidation matures, the number of attractive bolt-on targets shrinks. Multiples for even niche assets are already elevated. And strategic buyers may eventually reach a point where they've aggregated enough scale and capabilities that further acquisitions deliver diminishing returns.

But we're not there yet. TJO@Pack's exit shows there's still a functioning market for mid-market CDMO assets, and still buyers willing to pay for geographic and capability expansion. Ampersand got out at the right time. Whether Alcami and GTCR can say the same when they eventually exit will depend on how much longer this consolidation wave runs — and whether the fundamentals support the valuations being paid.